These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 38024817

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T, Feng L.
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH, Nurdayana AK, Rusni D, Azwany Y.
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical diagnostic significance of 14-3-3η protein, high-mobility group box-1, anti-cyclic citrullinated peptide antibodies, anti-mutated citrullinated vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
    Huang J, Zeng T, Zhang X, Tian Y, Wu Y, Yu J, Pei Z, Liu Y, Hu T, Tan L.
    Br J Biomed Sci; 2020 Jan; 77(1):19-23. PubMed ID: 31433746
    [Abstract] [Full Text] [Related]

  • 7. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O, Martinez-Gamboa L, Egerer K, Bang H, Fredenhagen G, Roggenbuck D, Esaulenko I, Burmester GR, Chernykh T, Feist E.
    Clin Exp Rheumatol; 2014 Jan; 32(5):622-9. PubMed ID: 25189876
    [Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G.
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [Abstract] [Full Text] [Related]

  • 9. Unique correlation between mutated citrullinated vimentine IgG autoantibodies and markers of systemic inflammation in rheumatoid arthritis patients.
    Zahran WE, Mahmoud MI, Shalaby KA, Abbas MH.
    Indian J Clin Biochem; 2013 Jul; 28(3):272-6. PubMed ID: 24426223
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis.
    Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, Gervasi G, Ménard JF, Gayet A, Fardellone P, Daragon A, Jolivet M, le Loët X, Tron F.
    Clin Exp Immunol; 2004 Jan; 135(1):173-80. PubMed ID: 14678280
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
    Keskin G, Inal A, Keskin D, Pekel A, Baysal O, Dizer U, Sengül A.
    Protein Pept Lett; 2008 Jan; 15(3):314-7. PubMed ID: 18336364
    [Abstract] [Full Text] [Related]

  • 13. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J.
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis.
    Zeng X, Ai M, Tian X, Gan X, Shi Y, Song Q, Tang F.
    J Rheumatol; 2003 Jul; 30(7):1451-5. PubMed ID: 12858440
    [Abstract] [Full Text] [Related]

  • 15. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria?
    Zhu JN, Nie LY, Lu XY, Wu HX.
    Clin Chem Lab Med; 2019 Oct 25; 57(11):1668-1679. PubMed ID: 31141478
    [Abstract] [Full Text] [Related]

  • 16. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC, Kaya S, Savaş S, Cetin ES, Akkuş S, Demirci M.
    Mikrobiyol Bul; 2008 Oct 25; 42(4):669-74. PubMed ID: 19149089
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H, Sugii S, Ozawa Y, Tohma S.
    J Rheumatol; 2006 Dec 25; 33(12):2390-7. PubMed ID: 16924694
    [Abstract] [Full Text] [Related]

  • 18. Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis.
    Hu T, Liu Y, Tan L, Huang J, Yu J, Wu Y, Pei Z, Zhang X, Li J, Song L, Dai W, Xiang Y.
    Br J Biomed Sci; 2021 Apr 25; 78(2):67-71. PubMed ID: 32813981
    [Abstract] [Full Text] [Related]

  • 19. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
    Agrawal S, Misra R, Aggarwal A.
    Clin Rheumatol; 2007 Feb 25; 26(2):201-4. PubMed ID: 16572283
    [Abstract] [Full Text] [Related]

  • 20. Antibodies to citrullinated peptides in tuberculosis.
    Lima I, Oliveira RC, Atta A, Marchi S, Barbosa L, Reis E, Reis MG, Santiago MB.
    Clin Rheumatol; 2013 May 25; 32(5):685-7. PubMed ID: 23344687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.